Journal of clinical and experimental hematopathology : JCEH最新文献_第2页

Surface CD3-negative monomorphic epitheliotropic intestinal T-cell lymphoma. 表面cd3阴性单形上皮性肠t细胞淋巴瘤。

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2022-09-28 Epub Date: 2022-08-18 DOI: 10.3960/jslrt.22005

Hideharu Domoto, Takahiro Araki, Asuka Ogai, Michiko Inukai, Chien K Chen, Sakura Tomita, Kiyoshi Mukai, Naoya Nakamura

{"title":"Surface CD3-negative monomorphic epitheliotropic intestinal T-cell lymphoma.","authors":"Hideharu Domoto, Takahiro Araki, Asuka Ogai, Michiko Inukai, Chien K Chen, Sakura Tomita, Kiyoshi Mukai, Naoya Nakamura","doi":"10.3960/jslrt.22005","DOIUrl":"https://doi.org/10.3960/jslrt.22005","url":null,"abstract":"Intestinal T/NK-cell lymphomas include enteropathy-associated T-cell lymphoma (EATL), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), indolent T-cell lymphoproliferative disorders of the GI tract (ITCLPD), extranodal NK/T-cell lymphoma, nasal type (ENKTL), and intestinal T-cell lymphoma NOS (ITCL-NOS). Here we describe a case of surface CD3-negative MEITL. A 63-year-old Japanese female had a tumor located in the conglomerated ileum, which formed multiple mass lesions. The resected tissue showed a diffuse infiltration of monomorphic medium-sized lymphocytes with epitheliotropism. Flowcytometry using a fresh specimen of the tumor revealed positivity for CD7, CD8, CD38, and CD56, but not surface CD3. On immunohistochemistry, the tumor showed positivity for cytoplasmic CD3, CD8, CD56, TIA-1, Granzyme B, and perforin. EBER with in situ hybridization was negative. Moreover, H3K36me3, which is negative in MEITL with SETD2-mutation, was positive. This is an important case of MEITL due to its oncogenesis.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"169-174"},"PeriodicalIF":1.5,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/46/4e/jslrt-62-169.PMC9635036.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40719536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term remission of primary refractory ALK-positive anaplastic large cell lymphoma after allogeneic hematopoietic stem cell transplantation. 同种异体造血干细胞移植后原发性难治性alk阳性间变性大细胞淋巴瘤的长期缓解。

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2022-09-28 Epub Date: 2022-06-22 DOI: 10.3960/jslrt.22003

Masahiro Miyazaki, Satoshi Ichikawa, Yasushi Onishi, Noriko Fukuhara, Eijiro Furukawa, Koichi Onodera, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae

{"title":"Long-term remission of primary refractory ALK-positive anaplastic large cell lymphoma after allogeneic hematopoietic stem cell transplantation.","authors":"Masahiro Miyazaki, Satoshi Ichikawa, Yasushi Onishi, Noriko Fukuhara, Eijiro Furukawa, Koichi Onodera, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae","doi":"10.3960/jslrt.22003","DOIUrl":"https://doi.org/10.3960/jslrt.22003","url":null,"abstract":"ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) has a favorable prognosis in general; however, some cases are resistant to chemotherapy, which leads to a poor clinical outcome. We herein report the case of a 32-year-old male with aggressive ALK+ ALCL who presented with hemorrhage from a large tumor in the duodenum and multiple tumors in the lungs, mediastinum, and peritoneal cavity. Although induction chemotherapy resulted in a marked reduction of the tumor lesions, premature progression with massive pulmonary infiltration and central nervous system invasion occurred immediately after the completion of chemotherapy. The patient was then promptly treated with brentuximab vedotin (BV) and high-dose methotrexate, which resulted in complete remission. Subsequently, he successfully underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an unrelated donor and has been healthy and did not relapse for more than 3 years after transplantation without any additional therapy. Allo-HSCT may be a promising treatment option for ALK+ ALCL due to its graft-versus-lymphoma effect. In addition, molecular targeting agents, such as BV, may be promising as a bridging therapy before allo-HSCT to achieve disease remission.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"164-168"},"PeriodicalIF":1.5,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/13/c1/jslrt-62-164.PMC9635028.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40193357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CD19 immunostaining of a stored paraffin-embedded vitrectomy cell block of intraocular lymphoma contributing to chimera antigen receptor T-cell therapy. 保存的石蜡包埋玻璃体切除细胞块对嵌合体抗原受体t细胞治疗的CD19免疫染色。

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2022-09-28 Epub Date: 2022-06-22 DOI: 10.3960/jslrt.22007

Toshihiko Matsuo, Takehiro Tanaka, Nobuharu Fujii, Kentaro Fujii, Eisei Kondo

{"title":"CD19 immunostaining of a stored paraffin-embedded vitrectomy cell block of intraocular lymphoma contributing to chimera antigen receptor T-cell therapy.","authors":"Toshihiko Matsuo, Takehiro Tanaka, Nobuharu Fujii, Kentaro Fujii, Eisei Kondo","doi":"10.3960/jslrt.22007","DOIUrl":"https://doi.org/10.3960/jslrt.22007","url":null,"abstract":"autologous peripheral blood hematopoietic stem cell transplantation in preconditioning with busulfan and thiotepa. 5 She maintained complete remission for 3 years until the age of 50 years when head magnetic resonance imaging showed high-signal lesions on the T2-weighted FLAIR image again in the right occipital lobe. She had 5 courses of methotrexate CHOP chemotherapy combined with rituximab for half a year, leading to complete remission, and then underwent chimera antigen receptor T-cell therapy (tisagenlecleucel) based on the CD19 expression of lymphoma cells in the preserved vitrectomy cell block (Fig. 1C). One year later, she devel-oped impending branch retinal vein occlusion with retinal blot hemorrhages, venous dilation and tortuosity in the right eye, and showed spontaneous resolution in the 4 months. Otherwise, she had shown neither retinal manifestations nor recurrent vitreous opacity throughout the course. She was systemically well for 1.5 years and maintained the best-cor-rected visual acuity of 1.5 in both eyes until the latest follow-up at the age of 52 years.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"187-189"},"PeriodicalIF":1.5,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/f2/jslrt-62-187.PMC9635033.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40193358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance. 伊鲁替尼在日本治疗复发/难治性CLL和SLL的疗效和安全性:上市后监测

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2022-09-28 Epub Date: 2022-07-12 DOI: 10.3960/jslrt.22002

Ai Omi, Fumi Nomura, Shigeharu Tsujioka, Akiko Fujino, Reiko Akizuki

{"title":"Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance.","authors":"Ai Omi, Fumi Nomura, Shigeharu Tsujioka, Akiko Fujino, Reiko Akizuki","doi":"10.3960/jslrt.22002","DOIUrl":"https://doi.org/10.3960/jslrt.22002","url":null,"abstract":"Ibrutinib is approved in Japan for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) based on the results of global and domestic clinical studies. Following approval, we conducted an all-case post-marketing surveillance in Japanese patients with relapsed/refractory CLL/SLL newly initiated on ibrutinib treatment between May 2016-September 2017. Of the 323 patients enrolled, the safety and efficacy analysis sets comprised 289 and 205 patients, respectively. The overall response rate with ibrutinib treatment was 64.4%, and the estimated 52-week progression-free survival (PFS) and overall survival (OS) rates were 71.7 and 79.1%, respectively. No significant difference in the PFS rate was observed among patients with and without del(17p) (P = 0.160); however, PFS was significantly longer in patients who received 1 prior line of therapy versus >1 prior lines of therapy (P = 0.007). Adverse events occurred in 74.0% of patients, and typically occurred early (≤12 weeks) after ibrutinib initiation, followed by a decline in incidence thereafter. The overall rates of infection, bleeding, and arrhythmia were 22.5, 12.8, and 4.8%, respectively. Grade ≥3 bleeding events and atrial fibrillation occurred in 2.4% of patients each. The efficacy and safety profile of ibrutinib treatment in routine clinical practice was consistent with clinical trials and previously reported domestic data.UMIN-CTR Clinical Trials Register ID: UMIN000021963.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"136-146"},"PeriodicalIF":1.5,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b4/23/jslrt-62-136.PMC9635026.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40587553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events. 布伦妥昔单抗维多汀治疗霍奇金淋巴瘤患者，由于胆管消失综合征导致肝功能障碍，导致部分反应，无任何严重不良事件。

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2022-09-28 Epub Date: 2022-07-12 DOI: 10.3960/jslrt.21035

Kantaro Ishitsuka, Yasuhisa Yokoyama, Naoko Baba, Ryota Matsuoka, Noriaki Sakamoto, Tatsuhiro Sakamoto, Manabu Kusakabe, Takayasu Kato, Naoki Kurita, Hidekazu Nishikii, Mamiko Sakata-Yanagimoto, Naoshi Obara, Yuichi Hasegawa, Shigeru Chiba

{"title":"Administration of brentuximab vedotin to a Hodgkin lymphoma patient with liver dysfunction due to vanishing bile duct syndrome resulting in a partial response without any severe adverse events.","authors":"Kantaro Ishitsuka, Yasuhisa Yokoyama, Naoko Baba, Ryota Matsuoka, Noriaki Sakamoto, Tatsuhiro Sakamoto, Manabu Kusakabe, Takayasu Kato, Naoki Kurita, Hidekazu Nishikii, Mamiko Sakata-Yanagimoto, Naoshi Obara, Yuichi Hasegawa, Shigeru Chiba","doi":"10.3960/jslrt.21035","DOIUrl":"https://doi.org/10.3960/jslrt.21035","url":null,"abstract":"Vanishing bile duct syndrome (VBDS) is a rare hepatic disorder which leads to liver failure as a result of progressive destruction of the intrahepatic bile ducts. There are no treatment modalities for VBDS itself and severe hepatic dysfunction restricts the treatment of underlying diseases. We safely treated a case of classic Hodgkin lymphoma (HL) with VBDS using brentuximab vedotin (BV). The patient was treated with 5 cycles of reduced BV and a partial metabolic response was obtained. Moreover, a standard dose of BV for another 5 cycles was accomplished with minimal adverse events. Our experience indicates that BV could be a treatment option for classic HL with VBDS.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"154-157"},"PeriodicalIF":1.5,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/b8/jslrt-62-154.PMC9635035.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40600808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Addition of bortezomib to high-dose cyclophosphamide therapy as a conditioning regimen for autologous peripheral blood stem cell harvest leads to an increased yield of hematopoietic stem cells. 在高剂量环磷酰胺治疗中加入硼替佐米作为自体外周血干细胞收获的调理方案，可增加造血干细胞的产量。

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2022-09-28 Epub Date: 2022-08-18 DOI: 10.3960/jslrt.22013

Sayaka Ohno, Kiyohito Hayashi, Ryo Shimizu, Akihiro Ishii, Hiroaki Tanaka

{"title":"Addition of bortezomib to high-dose cyclophosphamide therapy as a conditioning regimen for autologous peripheral blood stem cell harvest leads to an increased yield of hematopoietic stem cells.","authors":"Sayaka Ohno, Kiyohito Hayashi, Ryo Shimizu, Akihiro Ishii, Hiroaki Tanaka","doi":"10.3960/jslrt.22013","DOIUrl":"https://doi.org/10.3960/jslrt.22013","url":null,"abstract":"Peripheral blood stem cell harvest (PBSCH) is a crucial procedure for autologous stem cell transplantation in patients with multiple myeloma. We herein report a retrospective study to verify the usefulness of bortezomib and high-dose cyclophosphamide therapy (Bor-HDCY) as a conditioning regimen for PBSCH. Thirty-three patients were evaluated. The median age at the first apheresis was 61 (interquartile range, 53-64) years old, and 18 (54.5%) patients were male. Bor-HDCY was performed in 15 patients, and HDCY was performed in 18. In the patients who underwent Bor-HDCY, the CD34+ cell count at the first apheresis was significantly higher than in the others (P<0.01), and the total CD34+ cell count also tended to be high (P=0.0933). In terms of apheresis days, two-thirds of the patients who underwent HDCY had two-day apheresis, whereas most who underwent Bor-HDCY had one-day apheresis. According to univariate analysis, Bor-HDCY (P<0.01), VRd (Bor, lenalidomide, and dexamethasone) as induction therapy (P=0.0529), and ≥VGPR before PBSCH (P=0.0767) were factors associated with a higher CD34+ cell count at first apheresis. Although multivariate analysis showed that there were no independently significant factors influencing the CD34+ cell count at the first apheresis, the stepwise selection method revealed that only the Bor-HDCY regimen remained in the final model (P<0.005). Bor-HDCY may be a useful conditioning regimen for increasing the CD34+ cell yield.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"147-153"},"PeriodicalIF":1.5,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/06/5b/jslrt-62-147.PMC9635030.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40719537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Idiopathic plasmacytic lymphadenopathy: A conceptual history along with a translation of the original Japanese article published in 1980. 特发性浆细胞性淋巴结病:一个概念的历史与翻译原日本文章发表于1980年。

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2022-01-01 DOI: 10.3960/jslrt.22011

Kengo Takeuchi

引用次数: 6

Candidate biomarkers for idiopathic multicentric Castleman disease. 特发性多中心Castleman病的候选生物标志物。

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2022-01-01 DOI: 10.3960/jslrt.22010

Remi Sumiyoshi, Tomohiro Koga, Atsushi Kawakami

引用次数: 4

Castleman disease and mimickers: Clinicopathological findings of atypical lymphoproliferative disorders associated with autoimmune disease. Castleman病和模仿:与自身免疫性疾病相关的非典型淋巴增生性疾病的临床病理表现

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2022-01-01 DOI: 10.3960/jslrt.22025

Yoshimasa Nakazato, Shigeru Tsuchida, Atsuko Takada-Owada, Masato Onozaki, Shuhei Noda, Yumi Nozawa, Mina Takaoka, Kazuyuki Ishida

{"title":"Castleman disease and mimickers: Clinicopathological findings of atypical lymphoproliferative disorders associated with autoimmune disease.","authors":"Yoshimasa Nakazato, Shigeru Tsuchida, Atsuko Takada-Owada, Masato Onozaki, Shuhei Noda, Yumi Nozawa, Mina Takaoka, Kazuyuki Ishida","doi":"10.3960/jslrt.22025","DOIUrl":"https://doi.org/10.3960/jslrt.22025","url":null,"abstract":"Atypical lymphoproliferative disorders (LPDs) related with autoimmune disease (AID) show marked clinicopathological diversity, which are defined as three distinct clinicopathological subtypes such as those resembling Castleman disease (CD), atypical paracortical hyperplasia with lymphoid follicles (APHLF), and atypical lymphoplasmacytic and immunoblastic proliferation (ALPIB). We studied excisional biopsy specimens from 31 patients with atypical LPDs associated with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjögren syndrome (SjS). The lesions in these 31 cases were classified into 6 (19.4%) cases resembling CD, 14 (45.2%) cases of APHLF, and 11 (35.5%) cases of ALPIB. Five cases (83.3%) resembling CD were in the active stage with systemic symptoms and multicentric lymphadenopathy. Thirteen cases (92.9%) of APHLF showed systemic symptoms, multicentric lymphadenopathy and abnormal laboratory findings. Histologic findings for cases resembling CD were rare in patients with RA and SjS. In AID patients, histologic findings for cases resembling CD or APHLF findings correlated with disease activity and multicentric lymphadenopathy. Six cases (54.5%) of ALPIB were in the active phase with systemic symptoms and multicentric lymphadenopathy. ALPIB tended to be unrelated to AID activity, especially in the majority of patients with no abnormal laboratory findings. Atypical LPDs associated with AID is a group of diseases that may be overdiagnosed and overtreated. The diagnosis of atypical LPDs associated with AID requires an understanding of the histological findings as well as a comprehensive assessment of the presence of systemic symptoms, the distribution of lymphadenopathy, and abnormal laboratory findings.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"119-126"},"PeriodicalIF":1.5,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/81/4e/jslrt-62-119.PMC9635029.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40381595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Lymphoma Microenvironment in DLBCL and PTCL-NOS: the key to uncovering heterogeneity and the potential for stratification. DLBCL和PTCL-NOS的淋巴瘤微环境:揭示异质性和潜在分层的关键。

IF 1.5

Journal of clinical and experimental hematopathology : JCEH Pub Date : 2022-01-01 DOI: 10.3960/jslrt.22027

Kohta Miyawaki, Takeshi Sugio

{"title":"Lymphoma Microenvironment in DLBCL and PTCL-NOS: the key to uncovering heterogeneity and the potential for stratification.","authors":"Kohta Miyawaki, Takeshi Sugio","doi":"10.3960/jslrt.22027","DOIUrl":"https://doi.org/10.3960/jslrt.22027","url":null,"abstract":"Diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) are the most common subtypes of mature B cell neoplasm and T/NK cell lymphoma, respectively. They share a commonality in that they are, by definition, highly heterogeneous populations. Recent studies are revealing more about the heterogeneity of these diseases, and at the same time, there is an active debate on how to stratify these heterogeneous diseases and make them useful in clinical practice. The various immune cells and non-cellular components surrounding lymphoma cells, i.e., the lymphoma microenvironment, have been the subject of intense research since the late 2000s, and much knowledge has been accumulated over the past decade. As a result, it has become clear that the lymphoma microenvironment, despite its paucity in tissues, significantly impacts the lymphoma pathogenesis and clinical behavior, such as its prognosis and response to therapy. In this article, we review the role of the lymphoma microenvironment in DLBCL and PTCL-NOS, with particular attention given to its impact on the prognosis and stratification.","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"127-135"},"PeriodicalIF":1.5,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5a/bd/jslrt-62-127.PMC9635031.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40381596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3